ADVA
12.1.2021 09:02:30 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the expansion of its Ensemble Harmony Ecosystem to include disaggregated packet networking. Alpha Networks, Delta, Edgecore Networks and UfiSpace have all joined the open multi-vendor program. Each new member offers high-performance hardware platforms proven to interoperate with ADVA’s Ensemble Activator, a carrier-grade network operating system (NOS) specifically designed for white box switches. The Ensemble Harmony Ecosystem helps to accelerate softwarization and virtualization by offering service providers and enterprises access to the industry’s most comprehensive portfolio of flexible and disaggregated networking technologies. The addition of white box switch suppliers means it now delivers even more value to customers and helps to further simplify their transition to software-driven networking.
“Since the inception of NFV, our Ensemble Harmony Ecosystem has led the way, delivering unparalleled variety and choice of onboarded virtual network functions (VNFs). Now we’re opening up this unique multi-vendor environment to include some of the industry’s most innovative hardware suppliers, ensuring easy interoperability and new levels of collaboration for the rapid development of future services,” said James Buchanan, GM, Edge Cloud, ADVA. “This latest expansion of Ensemble Harmony will help more customers to realize the true value of virtualization and disaggregated packet networking as a catalyst to openness, componentized systems and innovation at the speed of software. The journey to white box switches and servers and software-driven networking is now simpler and more cost-efficient than ever before. ADVA is now the clear leader in network operating systems for white boxes.”
With the addition of leading hardware suppliers, ADVA’s open Ensemble Harmony Ecosystem provides everything service providers and businesses require to harness the power of disaggregated networking. Each of the new member companies offers highly efficient white box technology proven to interoperate successfully with ADVA’s Ensemble Activator , the first NOS designed for bare-metal switches. Already successful in trials with multiple global mobile network operators, including Telefónica and Vodafone, Ensemble Activator is the market’s most versatile operating system for disaggregated cell site gateways. When combined with Ensemble Harmony partner hardware, it offers new levels of agility and freedom and a clear route to cost-effective mass rollout of 5G services over large, geographically dispersed, multi-vendor networks.
“We’re excited to be among the first hardware partners to be welcomed into the Ensemble Harmony Ecosystem. It’s a community that shares our dedication to openness and interoperability. Together we can remove even more of the shackles of single-vendor proprietary solutions,” commented George Tchaparian, CEO, Edgecore Networks. “Today’s customers refuse to accept the constraints, the complexity and the expense of closed hardware and software systems. They demand the freedom to build scalable, cost-effective infrastructure on best-in-class open products and solutions. That’s why we’re working closely with Ensemble Harmony software partners, helping operators make the leap to virtualization and harness the benefits of openness and disaggregation.”
“ADVA’s Ensemble Harmony Ecosystem is a pillar of the open environment. Its philosophy is perfectly aligned with our own focus on disaggregation and open networking. What’s more, by collaborating with ADVA, we can add more value to our innovations and increase speed to market for our customers,” said Vincent Ho, CEO, UfiSpace. “We’ve been driving the next generation of open networking solutions with our carrier-grade disaggregated white box and network cloud solutions. Now, as part of Ensemble Harmony, we can give even more customers the freedom to choose from a wide range of fully integrated software and hardware technologies and select the ideal disaggregated solution for their business needs.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005057/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom